FDA approves treatment IND status for pentamidine.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000578:Amidines / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D006801:Humans; D010419:Pentamidine / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000578:Amidines; D000981:Antiprotozoal Agents; D010419:Pentamidine